(NASDAQ: EYPT) Eyepoint's forecast annual revenue growth rate of 96.29% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.66%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.47%.
Eyepoint's revenue in 2026 is $31,371,000.On average, 14 Wall Street analysts forecast EYPT's revenue for 2026 to be $473,392,884, with the lowest EYPT revenue forecast at $0, and the highest EYPT revenue forecast at $2,829,594,584. On average, 11 Wall Street analysts forecast EYPT's revenue for 2027 to be $5,044,045,401, with the lowest EYPT revenue forecast at $392,463,893, and the highest EYPT revenue forecast at $11,553,656,436.
In 2028, EYPT is forecast to generate $22,395,638,339 in revenue, with the lowest revenue forecast at $4,349,808,145 and the highest revenue forecast at $85,768,044,600.